Viral infections in lung transplantation.

Details

Ressource 1Download: 34992844_BIB_AFF818E6065F.pdf (620.70 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_AFF818E6065F
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Viral infections in lung transplantation.
Journal
Journal of thoracic disease
Author(s)
Munting A., Manuel O.
ISSN
2072-1439 (Print)
ISSN-L
2072-1439
Publication state
Published
Issued date
11/2021
Peer-reviewed
Oui
Volume
13
Number
11
Pages
6673-6694
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Viral infections account for up to 30% of all infectious complications in lung transplant recipients, remaining a significant cause of morbidity and even mortality. Impact of viral infections is not only due to the direct effects of viral replication, but also to immunologically-mediated lung injury that may lead to acute rejection and chronic lung allograft dysfunction. This has particularly been seen in infections caused by herpesviruses and respiratory viruses. The implementation of universal preventive measures against cytomegalovirus (CMV) and influenza (by means of antiviral prophylaxis and vaccination, respectively) and administration of early antiviral treatment have reduced the burden of these diseases and potentially their role in affecting allograft outcomes. New antivirals against CMV for prophylaxis and for treatment of antiviral-resistant CMV infection are currently being evaluated in transplant recipients, and may continue to improve the management of CMV in lung transplant recipients. However, new therapeutic and preventive strategies are highly needed for other viruses such as respiratory syncytial virus (RSV) or parainfluenza virus (PIV), including new antivirals and vaccines. This is particularly important in the advent of the COVID-19 pandemic, for which several unanswered questions remain, in particular on the best antiviral and immunomodulatory regimen for decreasing mortality specifically in lung transplant recipients. In conclusion, the appropriate management of viral complications after transplantation remain an essential step to continue improving survival and quality of life of lung transplant recipients.
Keywords
Pulmonary and Respiratory Medicine, Immunomodulatory effects, antiviral drugs, chronic lung allograft dysfunction (CLAD), herpesvirus, respiratory viral infections
Pubmed
Web of science
Open Access
Yes
Create date
13/08/2021 15:05
Last modification date
28/03/2023 5:52
Usage data